# A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Study · id `cardio:ct-nct01455857` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01455857](<https://clinicaltrials.gov/study/NCT01455857>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01455857

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.

## Technical summary

Registry record NCT01455857. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 460 participants (enrolled count; ClinicalTrials.gov record NCT01455857, source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)
- Start date: 2013-03 (registry gives no type) (ClinicalTrials.gov record NCT01455857, source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01455857, source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)
- Completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01455857, source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01455857, source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01455857-2015-08-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): ITCA 650
- Intervention (Other): ITCA placebo
- Lead sponsor: Intarcia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Intarcia Therapeutics (`cardio:org-intarcia-therapeutics`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial (`cardio:pubmed-29242349`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3e4c38d06d64b8a29f43fb6b3260c53af086fede16b83dd52d62cd1c9af1e280
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
